Weight-loss therapy set to push pharma growth
India’s obesity drug market is booming, poised for significant growth driven by rising lifestyle diseases and upcoming affordable generics. Experts anticipate wider access to GLP-1 medicines, accelerating innovation through AI, and a shift towards complex generics. This transformative phase promises improved patient outcomes and positions India as a key player in global healthcare advancements.🕒 1 min read
India’s obesity drug market is booming, poised for significant growth driven by rising lifestyle diseases and upcoming affordable generics. Experts anticipate wider access to GLP-1 medicines, accelerating innovation through AI, and a shift towards complex generics. This transformative phase promises improved patient outcomes and positions India as a key player in global healthcare advancements.
Continue Reading
- Are Hantavirus Tests Like Covid Tests? Doctors Explain Key Differences
-
Trump’s “Buyer Beware” Warning After “Dumb” Rant Over Tariff Verdict
- Probe Agency Freezes Anil Ambani Group Properties Worth Rs 581 Crore
-
NCP Workers’ 1 AM Rampage After Hotel Staff Objects To Dancing On Tables
-
The Fodder Scam Of The 1990s: When Corruption Brought Down Bihar’s Strongman Lalu Yadav
- Sebi brings back stock exchange buybacks, clears faster fundraising route for AIFs
- Trump Meets Pakistan PM Shehbaz Sharif, Army Chief Asim Munir In Latest Sign Of Warming Ties
-
Ayush Mhatre injury update: CSK’s Michael Hussey shares major concern
-
India’s GDP to grow 6.5% this FY: S&P
- 50 Days In Prison, 25 In Hotel, 19 Hours On Bus: Indian Man Returns From Iran
